| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
CAY10462 specifically targets CYP4A11, the enzyme responsible for the synthesis of 20-HETE from arachidonic acid. CYP4A11 is a member of the cytochrome P450 superfamily of enzymes that catalyze the ω-hydroxylation of arachidonic acid to produce 20-HETE. 20-HETE is a potent vasoconstrictor that plays important roles in the regulation of vascular tone, blood pressure, and renal function. The compound exhibits an IC50 of 8.8 nM for CYP4A11 inhibition when tested in human kidney microsomes. CAY10462 demonstrates significant selectivity, being nearly 200 times less potent against CYP450 1A, 1C, and 3A enzymes. This selectivity is important for minimizing off-target effects and for studying the specific role of CYP4A11 in 20-HETE production.
|
|---|---|
| ln Vitro |
The buildup of angiotensin II in endothelium intact aortic rings is increased when miconazole and CAY 10434 dihydrochloride (1 µM; 30 minutes) are combined [1].
In vitro, CAY10462 potently inhibits CYP4A11-mediated 20-HETE synthesis with an IC50 of 8.8 nM in human kidney microsomes. The compound demonstrates approximately 200-fold selectivity for CYP4A11 over CYP450 1A, 1C, and 3A enzymes, indicating a favorable selectivity profile. By inhibiting CYP4A11, CAY10462 reduces the production of 20-HETE, a potent vasoconstrictor that plays important roles in the regulation of vascular tone and blood pressure. The compound's potent and selective inhibition of 20-HETE synthase makes it a valuable tool for studying the role of 20-HETE in cardiovascular and renal physiology. |
| ln Vivo |
In vivo, CAY10462 has been investigated in preclinical models to study the role of 20-HETE in cardiovascular and renal physiology. By inhibiting CYP4A11 and reducing 20-HETE production, the compound is expected to modulate vascular tone and blood pressure. 20-HETE is a potent vasoconstrictor that is involved in the regulation of renal blood flow, sodium excretion, and blood pressure. The compound's potent and selective inhibition of 20-HETE synthase makes it a valuable tool for studying the physiological and pathophysiological roles of 20-HETE. Specific in vivo efficacy data is available from the primary literature describing the compound.
|
| Enzyme Assay |
The inhibitory activity of CAY10462 against CYP4A11 is assessed using enzyme activity assays with human kidney microsomes or recombinant CYP4A11. Microsomes are incubated with arachidonic acid and NADPH in the presence of varying concentrations of the test compound. The production of 20-HETE is quantified using LC-MS or GC-MS. IC50 values are calculated from dose-response curves. Selectivity against other CYP450 enzymes (1A, 1C, 3A) is assessed using similar assays with appropriate substrates. The compound's inhibition of 20-HETE synthase activity is confirmed by measuring the reduction in 20-HETE production.
|
| Cell Assay |
Cellular assays for CAY10462 are performed using cells that express CYP4A11, such as renal cells or cells transfected with CYP4A11 expression constructs. Cells are treated with varying concentrations of the compound for specified time periods. 20-HETE production is measured in cell supernatants or lysates using LC-MS. The compound's effects on cell viability and function are assessed using standard assays. CYP4A11 expression and activity can be confirmed by Western blotting and enzyme activity assays. The compound's selectivity can be confirmed by assessing its effects on other CYP450 enzymes in parallel assays.
|
| Animal Protocol |
In vivo studies of CAY10462 are conducted in animal models to study the role of 20-HETE in cardiovascular and renal physiology. The compound is typically administered via intraperitoneal (i.p.) injection or oral gavage. Blood pressure is measured using telemetry or tail-cuff methods. Renal blood flow and sodium excretion are assessed. 20-HETE levels are measured in plasma and tissues using LC-MS. Pharmacodynamic markers of CYP4A11 inhibition are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CAY10462 hydrochloride (molecular weight 360.32, molecular formula C17H27Cl2N3O) have been characterized. The compound is the dihydrochloride salt of CAY10434 and is formulated in suitable vehicles for in vivo administration. Storage recommendations include appropriate conditions for research chemicals. Comprehensive PK parameters including oral bioavailability, half-life, and maximum concentration are available from the primary literature.
|
| Toxicity/Toxicokinetics |
CAY10462 HCl is intended for research use only and is not approved for human therapeutic applications. Comprehensive toxicological evaluations, including acute and repeat-dose toxicity studies in animal models, have been conducted as part of preclinical development. The compound's mechanism of action—inhibiting 20-HETE synthase and reducing 20-HETE production—may affect vascular tone and blood pressure, and these effects would be carefully evaluated in toxicology studies. Standard safety pharmacology assessments would include evaluation of effects on cardiovascular and renal function.
|
| References | |
| Additional Infomation |
CAY10462 hydrochloride is the HCl salt of CAY10434 and functions as a selective inhibitor of 20-HETE synthase CYP4A11 with an IC50 of 8.8 nM. 20-HETE is a potent vasoconstrictor produced by cytochrome P450 enzymes that plays important roles in the regulation of vascular tone, blood pressure, and renal function. CAY10462 demonstrates approximately 200-fold selectivity for CYP4A11 over CYP450 1A, 1C, and 3A enzymes. The compound is a valuable research tool for studying the role of 20-HETE in cardiovascular and renal physiology and for validating CYP4A11 as a therapeutic target. CAY10462 is available with purity specifications for research use.
|
| Molecular Formula |
C17H27CL2N3O
|
|---|---|
| Molecular Weight |
360.323
|
| Exact Mass |
359.153
|
| Elemental Analysis |
C, 56.67; H, 7.55; Cl, 19.68; N, 11.66; O, 4.44
|
| CAS # |
502656-68-0
|
| Related CAS # |
CAY 10434;769917-29-5
|
| PubChem CID |
71433756
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.977
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
23
|
| Complexity |
265
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SRCWAJONAASSNJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H25N3O.2ClH/c1-19(2)12-5-3-4-6-14-21-17-9-7-16(8-10-17)20-13-11-18-15-20;;/h7-11,13,15H,3-6,12,14H2,1-2H3;2*1H
|
| Chemical Name |
1-Hexanamine, 6-[4-(1H-imidazol-1-yl)phenoxy]-N,N-dimethyl-, hydrochloride (1:2)
|
| Synonyms |
769917-29-5 (free base), 502656-68-0 (HCl),
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~35.71 mg/mL (~99.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7753 mL | 13.8766 mL | 27.7531 mL | |
| 5 mM | 0.5551 mL | 2.7753 mL | 5.5506 mL | |
| 10 mM | 0.2775 mL | 1.3877 mL | 2.7753 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
